Related Experiment Video
Updated: Jun 28, 2025
Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer
Published on: September 18, 2020
Alteration in DNA methylation patterns: Epigenetic signatures in gastrointestinal cancers
Zahra Heydari1, Farideh Moeinvaziri2, Seyed Mohammad Ali Mirazimi3
1Institute for Regenerative Medicine, Sechenov University, Moscow, Russia.
Abstract:
Abnormalities in epigenetic modifications can cause malignant transformations in cells, leading to cancers of the gastrointestinal (GI) tract, which accounts for 20% of all cancers worldwide. Among the epigenetic alterations, DNA hypomethylation is associated with genomic instability. In addition, CpG methylation and promoter hypermethylation have been recognized as biomarkers for different malignancies. In GI cancers, epigenetic alterations affect genes responsible for cell cycle control, DNA repair, apoptosis, and tumorigenic-specific signaling pathways. Understanding the pattern of alterations in DNA methylation in GI cancers could help scientists discover new molecular-based pharmaceutical treatments. This study highlights alterations in DNA methylation in GI cancers. Understanding epigenetic differences among GI cancers may improve targeted therapies and lead to the discovery of new diagnostic biomarkers.
Insights
Epigenetic alterations, including DNA methylation changes, are key drivers of gastrointestinal (GI) cancers. Understanding these DNA methylation patterns can lead to new targeted therapies and diagnostic biomarkers for GI malignancies.
Area of Science:
- Oncology
- Epigenetics
- Molecular Biology
Background:
- Epigenetic modifications, particularly DNA methylation, are implicated in cellular malignant transformation and cancer development.
- Gastrointestinal (GI) cancers represent a significant global health burden, accounting for 20% of all cancer cases worldwide.
- Specific epigenetic alterations like DNA hypomethylation, CpG methylation, and promoter hypermethylation are associated with genomic instability and serve as potential biomarkers in various malignancies.
Purpose of the Study:
- To highlight the alterations in DNA methylation patterns observed in GI cancers.
- To underscore the role of epigenetic changes in genes critical for cancer development, including cell cycle control, DNA repair, and apoptosis.
- To emphasize the potential of understanding DNA methylation in GI cancers for developing novel molecular-based pharmaceutical treatments and diagnostic biomarkers.
Main Methods:
- Review and analysis of existing literature on DNA methylation alterations in GI cancers.
- Identification of key epigenetic modifications and their impact on critical cancer-related genes.
- Correlation of DNA methylation patterns with genomic instability and potential biomarker applications.
Main Results:
- Abnormal DNA methylation patterns are prevalent in GI cancers, affecting genes involved in crucial cellular processes.
- DNA hypomethylation is linked to genomic instability, while CpG and promoter hypermethylation can serve as malignancy biomarkers.
- Epigenetic alterations in GI cancers impact cell cycle regulation, DNA repair mechanisms, apoptosis, and tumorigenic signaling pathways.
Conclusions:
- Understanding the specific patterns of DNA methylation alterations in GI cancers is crucial for advancing therapeutic strategies.
- Epigenetic differences among various GI cancers offer opportunities for developing more precise targeted therapies.
- Further research into DNA methylation in GI cancers may lead to the discovery of novel diagnostic biomarkers for early detection and personalized medicine.
Related Concept Videos
01:37Epigenetic Regulation
X-chromosome...
02:30Genomic Imprinting and Inheritance
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...